Nice article, and I agree. The recommendations: “Language in health care has ethical and practical implications. Physicians should be referred to as physicians, not providers. Also, when describing professionals with varied credentials who care for patients, the terms clinicians or health care professionals, not providers, should be used.” Physicians Are Not Providers: The Ethical Significance of Names in Health Care: A Policy Paper From the American College of Physicians | Annals of Internal Medicine acpjournals.org/doi/10.7326/…

Congratulations to Sean Domal, PhD, recipient of the inaugural RSS Early Career Physics Fellowship! See today's press release for more info therss.org/pr06102026 or visit therss.org/rss-early-career-…

Fantastic Gray Zone case and commentaries that touch on the key issues in managing esthesioneuroblastoma. A Scent of Doubt: The Dilemmas of Adjuvant Therapy in Esthesioneuroblastoma - International Journal of Radiation Oncology, Biology, Physics redjournal.org/article/S0360…

Working really hard to get FDA approval so all can get FMISO PET. ❤️❤️❤️

75% of patients received 30 Gy with FMISO PET based de-escalation for HPV-associated OPSCC. 30 Gy. Need the randomized data but hard to believe this won’t be the way. Incredible!

Such a critical point that applies to all disease sites comparing one radiotherapy modality with another. Modern IMRT/VMAT is really, really good, not just because of the quality of the delivery but because we have a better understanding of key OARs and how to avoid them. The challenge in improving on current outcomes is defining both the relevant dose metrics (beyond the "standard" for each disease site) and the relevant quality-of-life/bother endpoints that matter for patients in the long-run. I don't think that our current measures capture the entirety of the post-treatment patient experience, which is very difficult to quantify.

No QoL difference with IMPT vs IMRT in oropharyngeal cancer in the TORPEdO 🇬🇧 trial. How to explain the differences w/ @SJFrankMD 🇺🇸 trial? Planning? Patients? Crossover in the 🇺🇸 trial? Real absence of difference? Cc @EmmaHall71 @

Absolutely incredible work by @_ShankarSiva and colleagues! Wow. My question is how to engage our surgical and medical oncology trialist colleagues to test this paradigm versus primary surgery. @Raquib_Hannan Is this going to end up like bladder cancer?

There are tremendous opportunities to improve post-operative radiotherapy in HNSCC. The DIREKHT trial is an excellent example of such work, in which they spared the contralateral neck in a specified group of patients and/or reduced the primary CTV dose to 56 Gy. The details are important, as over 60% of patients had contralateral (path-negative) neck dissections (from prior publication). Putting aside the controversy of sparing an un-dissected contralateral neck for an oropharynx (non-tonsil) or oral cavity cancer, there is still hesitance to spare a path-negative contralateral neck. This paper helps assuage those fears. In the original publication, there were 3 contralateral-only LN recurrences, all in un-dissected necks. That means there were zero solitary nodal recurrences in 92 patients with a path-negative contralateral neck dissection, now with long-term follow-up. If a contralateral neck has been adequately dissected and is negative, it's hard to justify additional treatment to that hemi-neck. It's difficult to judge the 56 Gy outcomes by abstract alone, especially since the cohort mixed HPV-positive OPC and oral cavity. Extremely informative trial!

Two of our faculty, Drs. @MonaArbabMD and Aurelie Garant, along with one of our fellows, Dr. @DrSymYoung, having a great time this weekend at #ESTRO26!

JCOG 1208 is a nice study of ENI dose (46 Gy/23 fx) and volume reduction, without any solitary elective neck failures; another trial that supports ENI de-intensification. However, we cannot be satisfied with 79% locoregional PFS, especially for oropharyngeal cancer. Even with T1-2 N0-1 disease, sometimes concurrent chemotherapy may be needed.

Day TWO of #ESTRO26 Coverage by OncoAlert 🚨 Paradigm shift from bilateral elective nodal irradiation to SPECT/CT-based SNP to guide unilateral irradiation in HNSCC: multicenter prospective study Presented by Abrahim Al-Mamgani🇳🇱 SPECT/CT- and SN-guided selection tool for unilateral nodal irradiation (UNI) in patients with HNSCC is feasible, safe and very effective, as only 2 patients developed CRF (2.4%) with significant reduction of acute and late toxicity, compared to patients treated to both sides of the neck. Adding SNP to SEPCT/CT increased number of patients treated with UNI from 78% using only SPECT/CT to 91% by using combination of SPECT/CT- and SNP #RadOnc @ESTRO_RT @yasemin09896924 @LindaMrissa @christian_roenn @Valeriadionisi @gerryhanna @clchiang_hk @mtugceyilmaz @B_Tomasik @gmpetrianni @CiroFranzese1 @Atem84 @piet_ost @brachyexpert @BlanceS90 @The_PT_Explorer @BarbaraJereczek @Mat_Guc @ZilliThomas @AnnaKirby17 @PBlanchardMD @achoud72 Pinging OA faculty @MKnoll_MD @_ShankarSiva @Icro_Meattini @seanmmcbride @NiuSanford @nataliagandur @acampsmalea @to_be_elizabeth

Our Senior Director of Clinical Physics, Dr. @MHLinPhD, presented a poster titled "Feasibility of Direct-to-Treatment Ultra-Hypofractioned Whole Breast VMAT using AI-Assisted CBCT-Guided Adaptive Radiotherapy," this morning at #ESTRO26.

Excited to share our publication in @TheLancetOncol on the primary results from the UNITED study: a new paradigm in radiotherapy for patients with glioblastoma /1 @Sunnybrook @UofTDRO thelancet.com/journals/lanon…